Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2015 1
2016 1
2017 12
2018 3
2019 8
2020 5
2021 4
2022 2
2023 3

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape.
Li Y, Basar R, Wang G, Liu E, Moyes JS, Li L, Kerbauy LN, Uprety N, Fathi M, Rezvan A, Banerjee PP, Muniz-Feliciano L, Laskowski TJ, Ensley E, Daher M, Shanley M, Mendt M, Acharya S, Liu B, Biederstädt A, Rafei H, Guo X, Melo Garcia L, Lin P, Ang S, Marin D, Chen K, Bover L, Champlin RE, Varadarajan N, Shpall EJ, Rezvani K. Li Y, et al. Among authors: rafei h. Nat Med. 2022 Oct;28(10):2133-2144. doi: 10.1038/s41591-022-02003-x. Epub 2022 Sep 29. Nat Med. 2022. PMID: 36175679 Free PMC article.
Hereditary myeloid malignancies.
Rafei H, DiNardo CD. Rafei H, et al. Best Pract Res Clin Haematol. 2019 Jun;32(2):163-176. doi: 10.1016/j.beha.2019.05.001. Epub 2019 May 3. Best Pract Res Clin Haematol. 2019. PMID: 31203998 Free PMC article. Review.
Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering.
Li L, Mohanty V, Dou J, Huang Y, Banerjee PP, Miao Q, Lohr JG, Vijaykumar T, Frede J, Knoechel B, Muniz-Feliciano L, Laskowski TJ, Liang S, Moyes JS, Nandivada V, Basar R, Kaplan M, Daher M, Liu E, Li Y, Acharya S, Lin P, Shanley M, Rafei H, Marin D, Mielke S, Champlin RE, Shpall EJ, Chen K, Rezvani K. Li L, et al. Among authors: rafei h. Sci Adv. 2023 Jul 28;9(30):eadd6997. doi: 10.1126/sciadv.add6997. Epub 2023 Jul 26. Sci Adv. 2023. PMID: 37494448 Free PMC article.
Editorial: Cellular Therapies in Cancer.
Rafei H, Mehta RS, Rezvani K. Rafei H, et al. Front Immunol. 2019 Nov 27;10:2788. doi: 10.3389/fimmu.2019.02788. eCollection 2019. Front Immunol. 2019. PMID: 31827476 Free PMC article. No abstract available.
Targeting advanced urothelial carcinoma-developing strategies.
Alhalabi O, Rafei H, Shah A, Siefker-Radtke A, Campbell M, Gao J. Alhalabi O, et al. Among authors: rafei h. Curr Opin Oncol. 2019 May;31(3):207-215. doi: 10.1097/CCO.0000000000000532. Curr Opin Oncol. 2019. PMID: 30844889 Review.
Landscape of Immunotherapy in Genitourinary Malignancies.
Ravindranathan D, Alhalabi O, Rafei H, Shah AY, Bilen MA. Ravindranathan D, et al. Among authors: rafei h. Adv Exp Med Biol. 2021;1342:143-192. doi: 10.1007/978-3-030-79308-1_5. Adv Exp Med Biol. 2021. PMID: 34972965 Review.
Immune-based Therapies for Non-small Cell Lung Cancer.
Rafei H, El-Bahesh E, Finianos A, Nassereddine S, Tabbara I. Rafei H, et al. Anticancer Res. 2017 Feb;37(2):377-387. doi: 10.21873/anticanres.11330. Anticancer Res. 2017. PMID: 28179283 Review.
37 results